AstraZeneca COVID vaccine linked to another rare blood clotting disorder
A new research has linked AstraZeneca's COVID-19 vaccine to an increased risk of a rare but fatal blood clotting disorder known as Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT). The findings came almost a month after the giant phara admitted that its COVID-19 vaccines "Covishield" and "Vaxzevria" may cause Thrombosis Thrombocytopenia Syndrome (TTS) in rare cases. TTS is a rare condition characterized by a decrease in platelet count and the formation of blood clots in unusual places of the body.